Compare iShares Global Clean Energy ETF (ICLN) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs ResMed Inc. — how do they compare? iShares Global Clean Energy ETF trades at $17.25 (market cap $2.27B), while ResMed Inc. trades at $228.17 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 14× iShares Global Clean Energy ETF's market cap, and ResMed Inc. pays a 1.16% dividend while iShares Global Clean Energy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Clean Energy ETF for 87 Days and ResMed Inc. for 51 Days on average.
| ICLN | RMD | |
|---|---|---|
Market Cap | $2.27B | $31.89B |
Volume | 6,845,064 | 618,314 |
52-Week High | $23.75 | $277.88 |
52-Week Low | $15.78 | $182.82 |
Typical Hold Time | 87 Days | 51 Days |
Sector | — | Health |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN trades at $17.17, down 0.81% with bearish technical signals from moving averages. The ETF shows neutral momentum oscillators but faces significant volatility compared to traditional energy peers. Recent news highlights ICLN's 57.2% maximum drawdown and higher expense ratio of 0.38% versus fossil fuel ETFs, though geopolitical tensions are driving renewed interest in renewable energy infrastructure.
The clean energy sector faces competitive pressure from higher-yielding traditional energy ETFs, but long-term growth prospects remain supported by global energy transition trends. Key risks include expense ratio disadvantages and sector volatility, while potential catalysts include increased renewable adoption driven by geopolitical and environmental factors.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
